Financing ·
Eupraxia Pharmaceuticals Inc. filed interim financial statements for the three and six months ended June 30, 2026…
EPRXEupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. filed interim financial statements for the three and six months ended June 30, 2026, reporting a net loss of $14.5 million ($0.23 per share) for the quarter and $27.1 million ($0.46 per share) for the period. The company raised approximately $58.6 million in net proceeds from an overnight public offering of common shares and pre-funded warrants completed on February 20, 2026. Cash and short-term investments totaled $133.7 million as of June 30, 2026. Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing drug delivery technologies for unmet medical needs.